ADMA Biologics reports year end 2016 financial results
ADMA Biologics reported the consolidated net loss for the 2016 year end was $19.5 million, or $(1.61) per share, versus a consolidated net loss of $18.0 million, or ($1.73) per share, in 2015. ADMA reported revenues of $10.7 million for the 2016 compared to $7.2 million for the year end 2015. February 24, 2017